Merck announced that Health Canada has granted approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma whose tumours express PD-L1 as determined by a validated test. This approval is based on the results from the Phase 3 KEYNOTE-811 trial, which demonstrated a statistically significant improvement in progression-free survival compared to placebo in combination with trastuzumab and chemotherapy in the intention-to-treat study population.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Senate Health, Education, Labor & Pensions Committee holds a hearing
- Pharmaceutical CEOs are set to testify on drug prices, NY Times reports
- Merck price target raised to $140 from $120 at Argus
- BioXcel Therapeutics completes patient enrollment in Phase 2 trial of BXCL701
- M & A News: Merck (NYSE:MRK) Snaps Up Elanco’s Aqua Unit for $1.3B
Questions or Comments about the article? Write to editor@tipranks.com